We analyzed the incidence, presenting features, risk factors of extramedullary (EM) relapse
occurring in acute promyelocytic leukemia (APL) treated with all-trans retinoic acid (ATRA) …

All-trans retinoic acid (ATRA) is now a standard agent for remission induction of acute
promyelocytic leukemia (APL). Recently, extramedullary relapse, which was a rare condition …

PURPOSE: Recent reports of extramedullary disease (EMD) at recurrence in acute
promyelocytic leukemia (APL) have raised increasing concern about a possible role of …

Using current treatment regimens, over 90% of patients with acute promyelocytic leukemia
will achieve complete remission (CR). However, approximately 30% of these patients will …

All-trans retinoic acid (ATRA) is currently recommended as standard treatment for acute
promyelocytic leukemia (APL). However there has been increasing concern that ATRA is …

BACKGROUND Extramedullary involvement is only occasionally observed in patients with
acute promyelocytic leukemia (APL) but has been said to occur more frequently after …

Purpose Acute promyelocytic leukemia (APL) with pretreatment WBC counts greater than
10,000/μL is still considered to carry a poorer prognosis than APL with WBC lower than …

Central nervous system involvement at first relapse in patients with acute promyelocytic
leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without …

Purpose We analyzed the incidence, risk factors, and outcome of therapy-related myeloid
neoplasms (t-MNs) in patients with acute promyelocytic leukemia (APL) in first complete …

BACKGROUND Extramedullary acute promyelocytic leukemia (APL) is rare, and said to be
more common after treatment with all‐trans retinoic acid (ATRA) than after any other …